Myriad Genetics | MYGN - Cash And Equivalent


Myriad Genetics reported $145.4M in Cash and Equivalent for its fiscal quarter ending in September of 2025.





Cash And Equivalent Change Date
Agilent USD 1.76B 31M Dec/2025
Becton, Dickinson and Co. USD 740M 99M Dec/2025
Bio-Rad Laboratories USD 529.8M 134M Dec/2025
Bruker USD 293.1M 201.1M Sep/2025
Danaher USD 4.62B 3.09B Dec/2025
Exact Sciences USD 956M 166.96M Dec/2025
Hologic USD 2.17B 208.5M Dec/2025
Illumina USD 1.42B 368M Dec/2025
J&J USD 19.71B 1.48B Dec/2025
Mettler Toledo International USD 69.06M 7.24M Sep/2025
Myriad Genetics USD 145.4M 71M Sep/2025
OraSure Technologies USD 216.48M 18.1M Sep/2025
Pacific Biosciences Of California USD 56.47M 1.66M Sep/2025
Quest Diagnostics USD 420M 12M Dec/2025
Quidel USD 169.8M 71.7M Dec/2025
Repligen USD 566.02M 182.73M Dec/2025
Revvity USD 919.86M 11.53M Dec/2025
Standard Biotools USD 129.42M 29.2M Sep/2025
Thermo Fisher Scientific USD 9.85B 7.87B Dec/2025
Veracyte USD 362.58M 47M Dec/2025
Waters USD 587.83M 128.71M Dec/2025